November 5, 2020
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-7010
InMed Pharmaceuticals Inc.
Registration Statement on Form S-1
Filed June 19, 2020, as amended
File No. 333-239319
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the Securities Act), InMed Pharmaceuticals Inc. (the Company) hereby respectfully requests that the Securities and Exchange Commission (the Commission) accelerate the effective date of the above-referenced Registration Statement (the Registration Statement) to November 9, 2020 at 5:00 p.m. (Eastern) or as soon thereafter as is practicable.
The Company also requests the Commission confirm the effective date and time of the Registration Statement in writing.
|INMED PHARMACEUTICALS INC.|
/s/ Eric A. Adams
Name: Eric A. Adams
Title: President & Chief Executive Officer
InMed Pharmaceuticals Inc, #310-815 West Hastings St., Vancouver, BC, Canada, V6C-1B4
www.inmedpharma.com Tel. 604.669.7207 Fax. 778.945.6800